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Summary
Background Progress in tuberculosis control worldwide, including achievement of 2015 global targets, requires 
adequate ﬁ nancing sustained for many years. WHO began yearly monitoring of tuberculosis funding in 2002. We used 
data reported to WHO to analyse tuberculosis funding from governments and international donors (in real terms, 
constant 2011 US$) and associated progress in tuberculosis control in low-income and middle-income countries 
between 2002 and 2011. We then assessed funding needed to 2015 and how this funding could be mobilised.
Methods We included low-income and middle-income countries that reported data about ﬁ nancing for tuberculosis to 
WHO and had at least three observations between 2002 and 2011. When data were missing for speciﬁ c country–year 
combinations, we imputed the missing data. We aggregated country-speciﬁ c results for eight country groups deﬁ ned 
according to income level, political and economic proﬁ le, geography, and tuberculosis burden. We compared absolute 
changes in total funding with those in the total number of patients successfully treated and did cross-country 
comparisons of cost per successfully treated patient relative to gross domestic product. We estimated funding needs 
for tuberculosis care and control for all low-income and middle-income countries to 2015, and compared these needs 
with domestic funding that could be mobilised.
Findings Total funding grew from $1·7 billion in 2002 to $4·4 billion in 2011. It was mostly spent on diagnosis and 
treatment of drug-susceptible tuberculosis. 43 million patients were successfully treated, usually for $100–500 per 
person in countries with high burdens of tuberculosis. Domestic funding rose from $1·5 billion to $3·9 billion per 
year, mostly in Brazil, Russia, India, China, and South Africa (BRICS), which collectively account for 45% of global 
cases, where national contributions accounted for more than 95% of yearly funding. Donor funding increased from 
$0·2 billion in 2002 to $0·5 billion in 2011, and accounted for a mean of 39% of funding in the 17 countries with the 
highest burdens (excluding BRICS) and a mean of 67% in low-income countries by 2011. BRICS and upper middle-
income countries could mobilise almost all of their funding needs to 2015 from domestic sources. A full response to 
the tuberculosis epidemic to 2015, including investments to tackle multidrug-resistant tuberculosis, will require 
international donor funding of $1·6–2·3 billion each year.
Interpretation Funding for tuberculosis control increased substantially between 2002 and 2011, resulting in impressive 
and cost-eﬀ ective gains. The increasing self-suﬃ  ciency of many countries, including BRICS, which account for 
almost half the world’s tuberculosis cases, is a success story for control of tuberculosis. Nonetheless, international 
donor funding remains crucial in many countries and more is needed to achieve 2015 targets.
Funding None.
Introduction
Tuberculosis remains a major global health problem 
despite the availability of treatment that is curative in 
about 90% of cases. In 2011, there were an 
estimated 8·7 million cases of tuberculosis and 1·4 million 
deaths.1 Tuberculosis is the second leading cause of death 
from an infectious disease worldwide (after HIV, which 
caused an estimated 1·7 million deaths in 2011).2 
Reduction of the burden of tuberculosis disease requires 
adequate and sustained ﬁ nancing for many years.
Global targets to reduce cases of, and deaths from, 
tuberculosis have been set for 2015.1 The tuberculosis-
related target in the Millennium Development Goals is 
that incidence should be falling by 2015. The Stop TB 
Partnership set targets to halve prevalence and mortality 
rates by 2015 compared with 1990. In 2006, WHO 
launched the Stop TB Strategy, its recommended 
approach to achievement of the 2015 targets.3 That same 
year, the Stop TB Partnership published its Global Plan 
to Stop TB, which was based on the Stop TB 
Strategy and set out the actions and funding needed 
between 2006 and 2015 for a full response to the 
tuberculosis epidemic, with the overall goal of meeting 
the 2015 global targets for reductions in cases of, and 
deaths from, tuberculosis.4 An update of this plan for 
the years 2011–15 was released in 2010.5 Key components 
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of the plan include increasing the number of patients 
detected and treated according to WHO’s recommended 
strategy, from 5·8 million in 2011, to 6·9 million 
by 2015 (which would be equivalent to more than 80% of 
projected incident cases in that year); ensuring that all 
previously treated patients and all new patients with 
known risk factors for multidrug-resistant (MDR) 
tuberculosis are tested for MDR tuberculosis 
by 2015 (including with recently endorsed rapid tests 
such as Xpert MTB/RIF); enrolment of all patients with 
conﬁ rmed MDR tuberculosis (projected to be 
around 300 000 in 2015) into second-line treatment; HIV 
testing of all patients with tuberculosis; and prompt 
starting of antiretroviral therapy (ART) in all HIV-positive 
patients with tuberculosis. By 2011, the incidence of 
tuberculosis was falling globally and mortality and 
prevalence had fallen by 41% and 36%, respectively, 
since 1990.1
In the past decade, major national and international 
eﬀ orts have been made to ﬁ nance and implement proper 
tuberculosis control to reach the 2015 targets. Actions 
include the establishment of the Global Fund to Fight 
AIDS, Tuberculosis and Malaria (Global Fund) in 2002, 
and UNITAID in 2006, as new ﬁ nancing mechanisms to 
ﬁ ght three of the leading infectious causes of death in 
developing countries. However, economic problems in 
donor countries since 2007 have put pressure on external 
resources, and scrutiny of value for money has increased.6
External ﬁ nancing for malaria and future funding needs 
for HIV have been assessed.7–9 The ﬁ rst estimates of global 
funding needs for tuberculosis were published in 2002,10 
and, since 2003, WHO’s yearly global tuberculosis reports 
have included ﬁ nancing analyses of 22 countries with the 
highest burdens of tuberculosis—the so-called high-
burden countries (HBCs)—that account for about 80% of 
the world’s cases of the disease and drive global 
epidemiological and ﬁ nancial trends in tuberculosis.1 
These countries are Afghanistan, Bangladesh, Brazil, 
Burma, Cambodia, China, Democratic Republic of the 
Congo, Ethiopia, India, Indonesia, Kenya, Mozambique, 
Nigeria, Pakistan, the Philippines, Russia, South Africa, 
Tanzania, Thailand, Uganda, Vietnam, and Zimbabwe. 
We present new analyses of tuberculosis ﬁ nancing 
based on data from a decade of global ﬁ nancial monitor-
ing at WHO. We assess trends in domestic and 
international donor funding between 2002 and 2011 in 
low-income and middle-income countries, both overall 
and for eight country groups. We then examine whether 
increased funding has been associated with progress in 
tuberculosis control and explore value for money in 
terms of the cost per patient successfully treated. 
We conclude by appraising domestic capacity to mobilise 
the resources needed until 2015, and the resulting 
balance needed from international donors, to inform 
mobilisation and allocation of national and international 
resources for global tuberculosis control in 2013 and 
future years.
Methods
Background
WHO began monitoring government and international 
donor ﬁ nancing for tuberculosis in 2002, which built on 
a system that was established in 1995 for yearly collection 
of data from national tuberculosis control programmes 
(NTPs) of member states.11 All data are stored in WHO’s 
global tuberculosis database. The standard methods used 
to compile, review, validate, and analyse these ﬁ nancial 
data have been fully described elsewhere.1,12 The appendix 
contains a detailed explanation of the methods used, 
including those speciﬁ c to our analyses.
Each year, WHO requests data from low-income and 
middle-income countries about funding for NTPs by 
category of expenditure and source of funding, and 
funding gaps by category of expenditure, in US dollars. 
Categories of expenditure on tuberculosis comprise: 
ﬁ rst-line drugs; NTP staﬀ ; programme management 
and supervision activities; laboratory supplies and 
equipment; advocacy, communications, and social 
mobilisation; community-based care; private–public mix 
approaches; tuberculosis and HIV collaborative 
activities; the Practical Approach to Lung Health; 
operational research including surveys; outpatient visits; 
and hospital admissions. Categories of expenditure on 
MDR tuberculosis are: second-line drugs; other items 
speciﬁ cally for programmatic management of patients 
with MDR tuberculosis; hospital admissions; and 
outpatient visits. Funding sources are national or local 
government, loans (both classiﬁ ed as domestic funding), 
grants from the Global Fund, and grants from other 
donors (donor funding).
WHO staﬀ  use methods to review and validate data that 
have remained consistent since 2002. These methods 
include routine checks for plausibility and consistency 
(including validation checks that are built into the online 
reporting system), discussions with country respondents 
to resolve queries, and triangulation with other data 
sources (eg, detailed budgets prepared with WHO 
tuberculosis budgeting instruments,13 economic 
evaluations,14,15 the Global Fund, the Organisation for 
Economic Co-operation and Development Creditor 
Reporting System) to review the data. Particular attention 
has always been given to the 22 HBCs (appendix).
Analysis
Among all 154 low-income and middle-income countries, 
we deﬁ ned eight country groups according to tuberculosis 
burden, political and economic proﬁ le, income level, and 
geography. These groups were not always mutually 
exclusive. We divided the HBCs into two groups: Brazil, 
Russia, India, China, and South Africa (BRICS), which 
have a high, and increasing political and economic, 
proﬁ le; and the 17 HBCs excluding BRICS. We deﬁ ned 
three additional groups on the basis of the in-
come classiﬁ cation of the World Bank—speciﬁ cally, 
low-income countries, middle-income countries, and 
See Online for appendix
For the online reporting system 
see http:/www.stoptb.org/tme
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upper-middle-income countries. The ﬁ nal three groups 
were Africa, Asia, and other regions. Data for at least 
3 years were required for our analyses (appendix) and 
countries were included or excluded accordingly.
When data were missing for a country in a speciﬁ c 
year, we used country-speciﬁ c linear regression models 
based on funding in the previous year, the number of 
patients treated, or gross domestic product (GDP) per 
person as predictors, to impute values (appendix). From 
the linear regression models, uncertainty bands were 
calculated for predicted values.
In a few countries (China and Russia are prominent 
examples), funding for tuberculosis reported by NTPs 
includes funding for all staﬀ , infrastructure, and other 
inputs necessary for hospital admissions and outpatient 
visits during tuberculosis treatment, because care is 
provided in tuberculosis-speciﬁ c hospitals and clinics 
that have dedicated budgets. In most countries, however, 
the funding used for inpatient and outpatient care for 
patients with tuberculosis is not captured in funding 
reported by NTPs. For these countries, we estimated the 
funding used for inpatient and outpatient care of patients 
by multiplying the number of outpatient visits and days 
of inpatient care per patient (reported by NTPs to WHO 
each year) by country-speciﬁ c estimates of their unit cost 
available from the WHO-CHOICE database16 and then by 
the total reported number of patients with tuberculosis.
We assumed that the costs of inpatient and outpatient 
care were fully ﬁ nanced by domestic sources in middle-
income countries. In some low-income countries, 
international donor funding could help to support 
inpatient and outpatient care, but amounts are not 
routinely reported either for tuberculosis speciﬁ cally or 
the health sector in general (national health accounts do 
not include this speciﬁ c breakdown). In probabilistic 
uncertainty analyses, we speciﬁ ed a uniform distribution 
for the share of funding for inpatient and outpatient care 
provided from domestic sources in low-income countries, 
with the percentage of NTP funding that was domestically 
ﬁ nanced (23%) as a minimum and 100% as a maximum.
To measure trends in real terms, we used the GDP 
implicit price deﬂ ator from the USA to convert all values 
to constant 2011 US dollars. We then aggregated country-
speciﬁ c results for eight country groups deﬁ ned 
according to income level, political and economic proﬁ le, 
geography, and tuberculosis burden.
We compared absolute changes in total funding (in real 
terms) with absolute changes in the total number of 
Low-income countries
(22% of burden)
Lower-middle-income countries 
(49% of burden)
Upper-middle-income countries
(23% of burden)
BRICS 
(45% of burden)
17 high-burden countries 
excluding BRICS 
(37% of burden)
Africa Benin, Burkina Faso, Burundi, Central 
African Republic, Chad, Democratic 
Republic of the Congo, Eritrea, Ethiopia, 
The Gambia, Guinea-Bissau, Kenya, 
Liberia, Madagascar, Malawi, Mali, 
Mauritania, Mozambique, Niger, 
Rwanda, Sierra Leone, Somalia, Togo, 
Uganda, Tanzania, Zimbabwe
Cameroon, Cape Verde, Republic of 
Congo, Côte d’Ivoire, Djibouti, Egypt, 
Ghana, Lesotho, Morocco, Nigeria, 
São Tomé and Príncipe, Senegal, 
Sudan, Swaziland, Zambia
Botswana, Gabon, Namibia, 
South Africa, Tunisia
South Africa Democratic Republic of the 
Congo, Ethiopia, Kenya, 
Mozambique, Nigeria, 
Tanzania, Uganda, Zimbabwe
Asia Bangladesh, Burma, Cambodia, Nepal Bhutan, India, Indonesia, Kiribati, 
Laos, Marshall Islands, Micronesia, 
Mongolia, Pakistan, Papua New 
Guinea, Philippines, Solomon Islands, 
Sri Lanka, Timor-Leste, Tonga, 
Vanuatu, Vietnam
China, Malaysia, Palau, Thailand, Tuvalu India, China Afghanistan, Bangladesh, 
Burma, Cambodia, Indonesia, 
Pakistan, Philippines, 
Thailand, Vietnam
Other Afghanistan, Haiti, Tajikistan Armenia, Bolivia, El Salvador, Georgia, 
Guatemala, Guyana, Honduras, 
Nicaragua, Paraguay, Moldova, Syria, 
Uzbekistan, West Bank and Gaza Strip, 
Yemen
Argentina, Brazil, Bulgaria, Colombia, 
Dominican Republic, Ecuador, Iran, 
Jamaica, Jordan, Latvia, Lebanon, 
Panama, Romania, Russia, Suriname, 
Venezuela
Brazil, Russia
Excluded Comoros, Guinea, Kyrgyzstan, 
North Korea
Albania, Belize, Fiji, Iraq, Samoa, 
South Sudan, Ukraine
Algeria, American Samoa, Angola, 
Antigua and Barbuda, Azerbaijan, 
Belarus, Bosnia and Herzegovina, Chile, 
Costa Rica, Cuba, Dominica, Grenada, 
Kazakhstan, Libya, Lithuania, Maldives, 
Mauritius, Mexico, Montenegro, Peru, 
Saint Lucia, Saint Vincent and the 
Grenadines, Serbia, Seychelles, 
Macedonia, Turkey, Turkmenistan, 
Uruguay
Low-income countries had gross national incomes (GNIs) of US$1025 or less per person in 2011, lower-middle-income countries had GNIs between $1026 and $4035 per person in 2011, and upper-middle-
income countries had GNIs between $4036 and $12 475 per person in 2011. 11 countries whose income is not categorised by the World Bank were excluded: Anguilla, Aruba, Bonaire Saint Eustatius and Saba, 
British Virgin Islands, Cook Islands, Montserrat, Nauru, Netherlands Antilles, Niue, Tokelau, and Wallis and Futuna.
Table 1: Country groups according to income level, political and economic proﬁ le, geography, and global tuberculosis burden in 2011
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patients successfully treated (which was calculated from 
the number of patients with tuberculosis and rates of 
treatment success oﬃ  cially reported by countries).1 
We also assessed the cost per successfully treated patient 
and made cross-country comparisons of how this 
indicator was related to GDP per person (a proxy for the 
cost of non-traded inputs, mainly labour) and the caseload 
of patients with tuberculosis (because economies of scale 
might be realised in countries with many patients).
We used datasets from the Global Plan to Stop 
TB 2011–2015 in combination with country-speciﬁ c 
planning and budgeting work with nine countries in 
January, 2013, to estimate funding needs for tuberculosis 
care and control to 2015.17 Because trend data were not 
needed for this analysis, we could include all low-income 
and middle-income countries. The only major exclusion 
from the estimates was ART for HIV-positive patients 
with tuberculosis because funding for ART does not 
typically ﬂ ow through NTPs and, as part of work 
undertaken in 2013 to inform prereplenishment 
meetings held by the Global Fund, WHO, UNAIDS, and 
other partners agreed that funding needs for ART for 
HIV-positive patients with tuberculosis should be 
included in estimates of HIV resource needs to avoid 
double-counting. We then compared funding needs with 
the domestic funding that could be mobilised. 
We considered two scenarios. The ﬁ rst scenario was that 
tuberculosis funding could increase (from a 2011 baseline) 
in line with International Monetary Fund (IMF) forecasts 
for growth in total government expenditures.18 
The second scenario had the same assumptions as the 
ﬁ rst, but also assumed that countries that currently 
underperform in domestic ﬁ nancing relative to their 
income level (ie, their ability to pay) and disease burden 
reach the level of the median performer by 2020. 
These scenarios were chosen to be fully consistent with 
the methods previously used to assess the potential to 
mobilise domestic funding for prevention, treatment, 
Figure 1: Total funding for tuberculosis care and control from government and international donor sources and GDP per person weighted by population and caseload worldwide (A), and in 
BRICS (B); the 17 other HBCs (C); upper-middle-income (D), lower-middle-income (E), and low-income (F) countries; Africa (G); Asia (H); and other regions (I)
Data are for 104 low-income and middle-income countries, 2002–11. Total funding includes funds received directly by NTPs and funds used for outpatient visits and inpatient care within general 
health-care systems that are not channelled through the NTP. For GDP per person weighted by caseload, an individual country’s contribution is weighted according to share of tuberculosis cases in the 
same country group. GDP=gross domestic product. BRICS=Brazil, Russia, India, China, South Africa. HBCs=high-burden countries. NTP=national tuberculosis programme. *Excludes South Africa. 
†Excludes India and China. ‡Excludes Brazil and Russia.
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and care of HIV.9 Further details are provided elsewhere,17 
and additional information is available from KF upon 
request. We used Stata (version 12.1) for all analyses.
Role of the funding source
No donor had any role in the decision to prepare this 
Article, the analyses and writing, or the decision to 
submit for publication. The corresponding author had 
access to all data and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
We were able to include 104 of 154 low-income and middle-
income countries in our analyses (table 1). 50 countries 
were excluded because the number of observations was 
too small (<three) to use in our imputation models. 
The 104 included countries had 94% of the world’s 
estimated tuberculosis cases and 88% of the world’s 
estimated cases of MDR tuberculosis in 2011.1 In these 
countries, the mean number of observations per country 
(out of a maximum of ten) was 7·3 (SD 0·23); it 
was 8·3 (0·71) for the 22 HBCs. 83 had six or more 
observations and, for most countries, between seven and 
ten observations were available (appendix). 14 of the 22 
HBCs had ten observations each (including China and 
India, which accounted for 36% of global cases of 
tuberculosis in 2011)1 and ﬁ ve had nine observations each. 
Country–year combinations for which ﬁ nancing data were 
missing (284 of 1040 [27%]) accounted for 13%  of reported 
tuberculosis cases during the study (ie, data were missing 
mainly from countries with a small share of cases).
In the 104 low-income and middle-income countries 
included in our analyses, total tuberculosis funding 
(domestic and international donor sources) grew in real 
terms from $1·7 billion in 2002, to $4·4 billion 
in 2011 (ﬁ gure 1). The increases ranged from 100% in 
Figure 2: Total funding from government and international donor sources for treatment of drug-susceptible tuberculosis and numbers of patients with tuberculosis treated with ﬁ rst-line 
drugs worldwide (A), and in BRICS (B); the 17 other HBCs (C); upper-middle-income (D), lower-middle-income (E), and low-income (F) countries; Africa (G); Asia (H); and other regions (I)
Data are for 104 low-income and middle-income countries, 2002–2011.Total funding includes that for drug and non-drug costs channelled through national tuberculosis programmes and for hospital 
care and outpatient visits in general health-care systems but excludes costs of second-line drugs for treatment of patients with multidrug-resistant tuberculosis. Treatment success for 2011 has not yet 
been reported; we assume it is equal to that in 2010. BRICS=Brazil, Russia, India, China, South Africa. HBCs=high-burden countries. *Excludes South Africa. †Excludes India and China. ‡Excludes Brazil 
and Russia.
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low-income countries to 177% in upper-middle-income 
countries. Increases in funding were accompanied by 
increases in the number of people successfully treated 
for tuberculosis, from 2·8 million in 2002, to 5·0 million 
in 2011; 43 million people were treated be-
tween 2002 and 2011 (ﬁ gure 2). The cost per patient 
successfully treated was $100–500 in most of the highest-
burden countries (ﬁ gure 3). More than 70% of the 
variation between countries was explained by GDP per 
person and the size of the caseload of patients with 
tuberculosis (p<0·0001 for both variables).
Domestic funding rose from $1·5 billion in 2002, to 
$3·9 billion in 2011 (ﬁ gure 4). Both categories of domestic 
funding (ie, that channelled through NTPs and that for 
inpatient and outpatient care) increased worldwide and in 
six of the eight country groups (appendix). The exceptions 
were the 17 HBCs excluding BRICS, and Asian countries 
excluding India and China, in which funding channelled 
through NTPs fell between 2010 and 2011. As a share of 
total funding, domestic funding dropped by 6–10% in low-
income and lower-middle-income countries (appendix). 
Domestic funding increased more slowly (62–170% in 
10 years) than did GDP per person (ﬁ gure 1), which rose 
by 90–249% between 2002 and 2011 (the rise was slowest 
in low-income countries and fastest in upper-middle-
income countries). Loans accounted for a small proportion 
(≤5%) of total domestic funding each year (data not 
shown).
Most of the increase in total domestic funding 
($1·7 billion [71%]) was accounted for by BRICS (which 
account for 45% of the world’s cases of tuberculosis) 
and other middle-income countries in Asia, Latin 
America, and Europe (ﬁ gure 4). In view of the magnitude 
of domestic funding in these country groups (69–98% 
of total funding per year) and BRICS in particular 
(>95% of total funding per year), domestic funding 
dominated total funding for tuberculosis globally 
(88–92% per year).
Donor funding grew from $0·2 billion in 2002, to 
$0·5 billion in 2011 (ﬁ gure 4), and accounted for a 
strikingly high proportion of total funding in some 
country groups. By 2011, donor funding repre-
sented 39% of total funding in the the 17 HBCs 
excluding BRICS, which account for 37% of the world’s 
tuberculosis cases, 42% of funding in African countries 
excluding South Africa, and 67% of total funding in 
low-income countries (25 of which are in Africa; 
table 2). Although donor funding accounted for a 
small proportion (3–5% in 2011) of total funding 
in upper-middle-income countries and BRICS, 
absolute amounts were large—eg, $153 million 
in BRICS in 2011 (29% of all donor funding). The 
Global Fund accounted for 64% of all donor funding 
during 2002–11, reaching a high of 80% ($0·4 billion) 
in 2011.
Most funding was used for diagnosis and treatment 
of drug-susceptible tuberculosis (appendix). Small 
amounts were used for diagnosis and treatment of 
MDR tuberculosis, although funding started to increase 
in BRICS, upper-middle-income countries, and countries 
in Europe and Latin America around 2006.
Despite growth in tuberculosis funding, NTPs were 
not able to mobilise all the funding that they estimated to 
be needed (ﬁ gure 5). Funding gaps (ie, the diﬀ erence 
between assessments by NTPs of funding needs for 
tuberculosis care and control and the actual amount of 
funds mobilised) persisted, and increased from 
$257 million in 2002, to $563 million in 2011. Funding 
gaps decreased only in BRICS, upper-middle-income 
countries, and countries outside Africa and Asia.
Figure 6 shows the funding needed for a full response 
to the tuberculosis epidemic in all low-income and 
middle-income countries to reach targets set in the Global 
Plan to Stop TB, compared with the funding that could be 
mobilised from domestic sources. The gap between the 
funding needed to 2015 and the funding that could be 
mobilised from domestic sources is even larger than the 
funding gaps reported by NTPs (ﬁ gure 5). By 2015, an 
annual yearly gap of $1·6 billion is estimated in the 
second scenario and $2·3 billion in the ﬁ rst scenario. 
BRICS and upper-middle-income countries could 
mobilise almost all the requisite resources from domestic 
sources, whereas, especially in low-income countries, the 
17 HBCs excluding BRICS, and Africa (excluding South 
Africa), international donor funding will be needed.
Figure 3: Cost per successfully treated patient with tuberculosis relative to GDP per person, by country
Data are for 104 low-income and middle-income countries. Countries with more than 100 000 cases per year are 
labelled. The area of the circle is proportional to the caseload. The shaded area represents the 99% CI. Costs per 
successfully treated patient are based on the 2008–10 case-weighted mean. Both axes are on a log scale. 
GDP=gross domestic product.
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Figure 4: Funding for tuberculosis care and control from domestic sources, international donors, and the Global Fund speciﬁ cally worldwide (A), and in 
BRICS (B); the 17 other HBCs (C); upper-middle-income (D), lower-middle-income (E), and low-income (F) countries; Africa (G); Asia (H); and other 
regions (I)
Uncertainty bands for domestic funding show uncertainty in years for which one or more countries did not report funding data or a breakdown of funding by 
source, and uncertainty about the extent to which inpatient and outpatient care for tuberculosis patients in general health-care systems are domestically funded in 
low-income countries. In probabilistic uncertainty analysis, the proportion of funding for inpatient and outpatient care funded from domestic sources in low-
income countries was assumed to follow a uniform distribution, ranging from the proportion of funding for national tuberculosis programmes from domestic 
sources to 100%. BRICS=Brazil, Russia, India, China, South Africa. HBCs=high-burden countries. *Excludes South Africa. †Excludes India and China. ‡Excludes Brazil 
and Russia.
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Domestic sources (5th–95th percentile) International donor sources (5th–95th percentile) Global Fund only (best estimate)
Africa* Asia† Other regions‡
Upper-middle-income countries Lower-middle-income countries Low-income countries
World BRICS 17 HBCs excluding BRICS
2002–11 2011
Donor 
funding 
(US$ millions)
Donor funding 
as % of total 
funding
Global Fund 
contributions as % 
of donor funding
Global Fund 
contributions as % 
of total funding
Donor 
funding 
(US$ millions)
Donor funding 
as % of total 
funding
Global Fund 
contributions as % 
of donor funding
Global Fund 
contributions as 
% of total funding
World 3075 10 64 6 523 12 80 10
BRICS 730 4 74 3 153 5 90 5
17 high-burden countries (excluding BRICS) 1303 34 54 18 199 39 69 27
Upper-middle-income countries 650 3 75 2 114 3 93 3
Lower-middle-income countries 1307 22 67 15 212 25 85 21
Low-income countries 1105 60 54 32 196 67 69 46
Africa excluding South Africa 1168 39 54 21 180 42 74 31
Asia excluding India and China 738 23 64 15 107 24 75 18
Other regions excluding Brazil and Russia 424 10 71 7 81 12 85 11
Figures are best estimates. Global Fund refers to the Global Fund to Fight AIDS, Tuberculosis and Malaria. BRICS=Brazil, Russia, India, China, South Africa.
Table 2: Funding received for tuberculosis care and control from international donor sources, 2002–11
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Discussion
Our study is, to our knowledge, the ﬁ rst to assess long-
term trends in government and international donor 
funding for care and control of tuberculosis in low-
income and middle-income countries (panel). It shows 
that funding grew substantially between 2002 and 2011, 
and that the number of people successfully treated for 
tuberculosis greatly increased (at a low cost per patient). 
Domestic funding has underpinned progress in BRICS 
and European, Latin American, and upper-middle-
income countries, and these countries are increasingly 
self-suﬃ  cient. Other countries remain highly dependent 
on international donor funding. Donor funding remains 
essential to safeguard and build on recent gains in 
tuberculosis control in these countries. Furthermore, 
despite growing investments, the yearly gap between the 
funding needed for a full response to the tuberculosis 
epidemic and the funding available could exceed 
$2 billion per year by 2015.
Our study has several strengths and limitations. 
We excluded 50 low-income and middle-income 
countries (which account for 4% of tuberculosis cases 
globally) from trend analyses because data were 
unavailable or too incomplete (including Kazakhstan, 
which reported funding of $0·2 billion in 2011), and 
country–year combinations for which data were imputed 
accounted for 13% of tuberculosis cases. Further eﬀ orts 
are needed to improve data for tuberculosis ﬁ nancing. 
However, in an analysis19 of global ﬁ nancing for public 
health in developing countries, 25–44% of data were 
imputed. Inclusion of these extra countries that account 
for only 4% of tuberculosis cases worldwide probably 
would not change our main results (or interpretations 
thereof).
Figure 5: Funding gaps reported by NTPs by major category of expenditure worldwide (A), and in BRICS (B); the 17 other HBCs (C); upper-middle-income (D), 
lower-middle-income (E), and low-income (F) countries; Africa (G); Asia (H); and other regions (I)
Data are for 104 low-income and middle-income countries, 2002–11. Basic DOTS (excluding ﬁ rst-line drugs) includes NTP staﬀ , programme management and 
supervision, laboratory supplies, hospital stays, and clinic visits. Enhanced DOTS includes collaborative tuberculosis and HIV activities; advocacy, communications, 
and social mobilisation; community-based care; private–public mix approaches; the Practical Approach to Lung Health; operational research; surveys; and other 
miscellaneous items. DOTS is the basic package that underpins the Stop TB Strategy. NTP=national tuberculosis programme. BRICS=Brazil, Russia, India, China, 
South Africa. HBCs=high-burden countries. MDR=multidrug-resistant. *Excludes South Africa. †Excludes India and China. ‡Excludes Brazil and Russia.
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Figure 6: Forecast of funding that could be mobilised from domestic sources compared with funding needed for a full response to the global tuberculosis 
epidemic in BRICS (A); the 17 other HBCs (B); low-income countries excluding HBCs (C); low-income (D), lower-middle-income (E), and upper-middle-income 
(F) countries; Africa (G); Asia (H); and the rest of the world (I)
The blue band represents scenario 1, which shows domestic funding that could be mobilised if domestic funding increases from a 2011 baseline at the same rate of 
growth as International Monetary Fund forecasts of growth in total government expenditures. The green band shows additional resources that could be mobilised, 
compared with scenario 1, if current underperformers (relative to income level and disease burden of tuberculosis) improve at a consistent rate to reach the level of 
the median performer by 2020. Amounts of total funding available from domestic sources in 2011 diﬀ er from those displayed in previous ﬁ gures because all 
low-income and middle-income countries were included, not only the 104 for which trends in tuberculosis funding could be estimated since 2002. Of total funding 
required (red line), about 60% is for the core elements of tuberculosis care and control (DOTS, the basic package that underpins the Stop TB Strategy), 25% is for 
treatment of multidrug-resistant tuberculosis, 10% is for rapid tests and associated laboratory strengthening, and 5% is for collaborative tuberculosis–HIV activities. 
Funding needs allow for inﬂ ation. BRICS=Brazil, Russia, India, China, South Africa. HBCs=high-burden countries. *Excludes India and China. †Excludes Brazil, Russia, 
and South Africa. ‡Excludes South Africa. §Excludes Brazil and Russia.
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We could not include analysis of out-of-pocket 
expenditures (which might be large in some countries, 
notably before diagnosis) and insurance schemes (which 
are of increasing relevance, especially in middle-income 
countries), which would increase total reported spending 
on tuberculosis. Unfortunately, these data are not 
routinely compiled for tuberculosis speciﬁ cally. We have 
also missed some donor funding for technical assistance 
provided directly to international agencies and donor 
funding provided directly to non-governmental organ-
isations, although these amounts are usually small 
compared with the total funding available to NTPs and 
are unlikely to aﬀ ect global trends. We did not include 
funding for development of drugs, diagnostic tests, or 
vaccines, which is monitored by others and amounted to 
$0·65 billion in 2011.20 Unlike some other studies,7 in 
our analysis we assessed both domestic and donor 
funding.
Other data sources and studies are broadly consistent 
with our results. For example, the total funding for 
tuberculosis provided by grants from the Global Fund 
that was reported by countries to WHO during 2002–11 is 
nearly identical to yearly disbursement ﬁ gures reported 
by the Global Fund for the same set of countries.21 Total 
donor funding from the Fund and bilateral agencies 
reported by the Institute of Health Metrics and 
Evaluation22 was slightly higher than that reported in our 
analysis, probably because we excluded some countries 
that receive donor funding and missed funding not 
channelled through NTPs.
Between 2002 and 2011, 43 million people were 
successfully treated for tuberculosis at a unit cost of 
usually $100–500 per person, which translates to less 
than $1250 per death averted (case fatality without 
treatment is about 40%)23 and less than $100 per year of 
life saved (assuming that at least 12·5 years of life are 
saved for every averted death). For an intervention to be 
deemed highly cost-eﬀ ective, the suggested benchmark 
is a cost per year of life saved less than GDP per person.24 
GDP per person is more than $100 in even the poorest 
countries. On this basis, investments in tuberculosis 
control have been highly cost-eﬀ ective, which has 
previously been suggested elsewhere.25–27 If the price of 
second-line drugs for treatment of MDR tuberculosis 
(currently around $2500–6000 per patient) could be 
lowered, and more outpatient-based models of care for 
tuberculosis and MDR tuberculosis adopted in some 
regions (notably eastern Europe and central Asia), the 
cost-eﬀ ectiveness of treatment of both tuberculosis and 
MDR tuberculosis could be further improved and 
funding requirements lowered in some settings.
Our ﬁ ndings show that much more funding is needed 
for a full response to the tuberculosis epidemic in low-
income and middle-income countries. Most funding has 
been spent on diagnosis and treatment of drug-
susceptible tuberculosis. Compared with 2011, additional 
funding of around $2–3 billion per year is needed to 
reach the 2015 targets set in the Global Plan to Stop TB, 
including those for detection and treatment of 
MDR tuberculosis, implementation of interventions that 
jointly address the coepidemics of tuberculosis and HIV, 
and increased uptake of innovations such as rapid tests. 
Clearly more domestic resources could be mobilised 
(possibly around $6·5 billion by 2015). BRICS and upper-
middle-income countries (mostly in Europe and Latin 
America) in particular can become increasingly, or, in 
some cases, fully, self-suﬃ  cient.
Insurance schemes might have an increasing role in 
some countries. They might become the main source of 
funding for diagnosis and treatment of MDR tuberculosis 
in China. International donor funding is crucial to ﬁ ll the 
remaining gap of around $1·6 billion per year. Tripling of 
donor investments in tuberculosis compared with those 
in 2011 might seem unrealistic. However, donor funding 
for tuberculosis remains small compared with 
Panel: Research in context
Systematic review
We searched PubMed in January, 2012, with several combinations of the search terms 
“health”, “ﬁ nancing”, “global”, and “trends”; “global”, “ﬁ nancing”, “trends”, and 
“tuberculosis”; “ﬁ nancing”, “international donor”, and “tuberculosis”; and “ﬁ nancial”, 
“monitoring”, and “tuberculosis”. Searches in which the term “tuberculosis” was 
substituted for HIV and malaria were also done. We reviewed ﬁ nancing data included in 
global reports published by WHO’s tuberculosis and malaria programmes, UNAIDS, and 
the Institute of Health Metrics and Evaluation. Our search of PubMed identiﬁ ed one 
previous study that included data for trends in domestic and donor ﬁ nancing for 
tuberculosis, covering the years 2002–07.12 We did not identify any study of global trends 
in domestic and international donor funding for tuberculosis covering the decade 2002–
11. A repeat search on March 25, 2013, did not identify any subsequent studies.
The main source of information for the analyses published in this Article was data provided 
in routine reports submitted to WHO by the national tuberculosis programmes of member 
states. These reports are submitted as part of yearly data collection organised by WHO’s 
Global TB Programme. Financial data have been gathered since 2002, and particular 
attention is given to low-income and middle-income countries. Our second source of 
information was estimates of unit costs for outpatient visits and bed days in hospital 
available from a global database managed by WHO’s health ﬁ nancing department. 
The analyses presented in this paper were restricted to the 104 countries for which data of 
suﬃ  cient completeness and quality were available. These countries account for 94% of the 
world’s tuberculosis cases and 88% of the world’s cases of multidrug-resistant tuberculosis. 
Interpretation
Funding for tuberculosis care and control grew substantially between 2002 and 2011, and 
impressive and cost-eﬀ ective gains were delivered. We noted striking contrasts in funding 
patterns between countries. The increasing self-suﬃ  ciency of countries such as Brazil, 
Russia, India, China, and South Africa (BRICS), where almost 50% of the world’s tuberculosis 
cases occur, is a success story for tuberculosis control. However, international donor funding 
remains essential to safeguard and build on gains in many countries. In high-burden 
countries outside BRICS and in all low-income countries, international donor funding 
accounted for between a quarter and two-thirds of total funding by 2011. International 
donor funding for tuberculosis is much less than the funding allocated for HIV and malaria. 
The yearly gap between the funding needed for a full response to the tuberculosis epidemic 
and that available could exceed US$2 billion by 2015. Despite growing investments in 
tuberculosis overall, more funding is needed to reach 2015 global tuberculosis targets.
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investments in HIV ($8·2 billion in 2011)2 and is 
about 25% of that allocated for malaria.28 These 
observations are a challenge to do better at resource 
mobilisation for tuberculosis care and control, globally 
and nationally. 
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